BRD4 Inhibition as a Strategy to Prolong the Response to Standard of Care in Estrogen Receptor-Positive Breast Cancer
Ahmed M. Elshazly(Kafrelsheikh University), David A. Gewirtz(Virginia Commonwealth University)
Cited by 11
Related Papers
The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer
|Frontiers in Oncology|2023|23
Studies of Non-Protective Autophagy Provide Evidence that Recovery from Therapy-Induced Senescence is Independent of Early Autophagy
|International Journal of Molecular Sciences|2020|17
A BPTF Inhibitor That Interferes with the Multidrug Resistance Pump to Sensitize Murine Triple-Negative Breast Cancer Cells to Chemotherapy
|International Journal of Molecular Sciences|2024|3
Reversibility of chemotherapy-induced senescence is independent of autophagy and a potential model for tumor dormancy and cancer recurrence
|bioRxiv (Cold Spring Harbor Laboratory)|2017|2